Regeneus Announces Successful Results in Acne Study
Filed with ASX · · 2 pages · English
Story so far
Earlier from Cambium Bio
- CEO Presentation to 2017 Annual General Meeting
- Sygenus shows longer lasting effect on pain than morphine
- Regeneus receives R&D tax incentive refund of $2.6m
- Appendix 4E Revised
- US patent allowed for Sygenus for acne
Later from Cambium Bio
- Japanese Patent Office to grant patent for cancer vaccine
- European Medicines Agency grants Progenza ATMP status
- Update on licensing Progenza in Japan
- US Patent Office to allow key patent for Progenza
- Positive clinical trial results for cancer vaccine
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio